GB1575800A - Spiro amines their production and compositions containing them - Google Patents

Spiro amines their production and compositions containing them Download PDF

Info

Publication number
GB1575800A
GB1575800A GB1995978A GB1995978A GB1575800A GB 1575800 A GB1575800 A GB 1575800A GB 1995978 A GB1995978 A GB 1995978A GB 1995978 A GB1995978 A GB 1995978A GB 1575800 A GB1575800 A GB 1575800A
Authority
GB
United Kingdom
Prior art keywords
spiro
group
piperidine
oxo
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1995978A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Priority to GB1995978A priority Critical patent/GB1575800A/en
Publication of GB1575800A publication Critical patent/GB1575800A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

(54) SPIRO AMINES, THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM (71) We, SUMITOMO CHEMICAL COMPANY LIMITED, a corporation organized under the laws of Japan, of 15, Kitahama-5-chome, Higashi-ku, Osaka, Japan, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is performed, to be particularly described in and by the following statement: The present invention relates to spiro amine derivatives having antihypertensive activity and central nervous system depressant activity, and to the preparation and use thereof.
More particularly, the present invention provides a spiro amine derivative of the general formula:
Wherein R' is a hydrogen atom, a C1 - C4 alkyl group, a phenyl group which is unsubstituted or substituted by a halogen atom, a Cl - C4 alkyl group or a C1 - C4 alkoxy group, R2 is absent or Rl and R2 together, form a C1 - C4 alkylene radical and thus together with the indolene nucleus define a ring, W is an oxygen atom or two hydrogen atoms and R is a group of the formula:
(wherein A is a C - C4 alkylene, X is absent or is a carbonylgroup, an oxygen atom, the radical )CH-OH or the radical -CG=CH- and R3, R4 and Rt are each optionally present and are each, independently of one another, a Cl - C4 alkyl group, a C1 - C4 alkoxy group, a- benzyloxy group, a halogen atom or a hydroxy group) or
(wherein R6 is a group of the formula:
(wherein R7 is optionally present and is a halogen atom, a cyano group, a C1 - C4 alkyl group, a C1 - C4 alkoxy group or a hydroxyl group),
(wherein R7 is as defined above) or
(wherein R7 is as defined above)), or a pharmaceutically acceptable salt, e.g. an acid addition or quaternary ammonium salt, thereof.
The "halogen" atom may be chlorine, fluorine, bromine or iodine; the C1 - C4 alkyl group may be a straight or branched chain alkyl group having from one to four carbon atoms inclusive (e.g. methyl, ethyl, isopropyl or butyl: the C1 - C4 alkoxy group is an alkoxy group having from one to four carbon atoms inclusive (e.g. methoxy, ethoxy or isopropoxy); the (S - L4 alkylene radical may he metnylene, ethylene, tnmethylene or tetramethylene.
We have found that spiro amine derivatives within the formula (I) as defined above have a hypotensive activity and are useful as anti-hypertensive agents. They also have a central nervous system depressant activity and are useful as transuqillizers and anti-psychotic agents.
Among the spiro amine derivatives of the formula (I) the preferred compounds are those in which W is an oxygen atom. Furthermore, particularly preferred compounds are those within any of the formulae:
wherein Rl, R2 R3 and R7 are each as defined above, and X is a carbonyl group or the radical -CH-OH.
For example, 1'-(3-(4-fluorobenzoyl)propyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine has a potent hypotensive activity at low dosages (0.1 mg/kg - 0.3 mg/kg ip).
In a process within the present invention, a spiro amine derivative of the formula (I) is prepared by reacting a compound of the formula:
wherein Y is absent or is a carbonyl group, a protected carbonyl group, an oxygen atomg the radical =CH-OH or the radical -CH=CH-, Z is a halogen atom and A, R3, R4 and R are as defined above, or a compound of the formula: R6 - B (III) wherein R6 is as defined above and B is a group of the formula:
(wherein Z is as defined above) with a spiro amine derivative of the formula:
wherein Rl, R2 and W are each as defined above, optionally followed by reduction of a carbonyl group, or by hydrolysis of a protected carbonyl group, and optionally salifying the resultant product.
A spiro amine derivative in which R3, R4 or R5 is a hydroxy group can also be prepared by debenzylation of the corresponding benzyloxy derivative.
The condensation reaction is usually carried out in an inert solvent such as an aromatic hydrocarbon (e.g. benzene, toluene, xylene), an amide (e.g. dimethyl-formamide, N,N-dimethylacetamide), an ether (e.g. dioxane, tetrahydrofuran), an alcohol (e.g.
ethanol, n-butanol, propanol, amyl alcohol), an alkanone (e.g. acetone, butanone, methyl isobutyl ketone) or dimethyl sulfoxide at a temperature within a range of from 0 C to the boiling point of the solvent inclusive. Preferably, a basic substance such as an alkali metal hydrogen carbonate (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate), an akali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide) or an organic amine (e.g.
pyridine, triethylamine) is used as an acid binding agent. A small amount of a reaction accelerating agent such as potassium iodide may also be added.
The hydrolysis can be carried out by conventional acid. hydrolyzing procedure. For instance, it can be accomplished by treating the protected compound with an acidic substance such as a mineral acid (e.g. hydrochloric acid, sulfuric acid, phosphoric acid), an organic acid (e.g. oxalic acid, tartaric acid) or an acidic ion exchange resin in water or an alkanol (e.g. methanol, ethanol, propanol), usually under mild conditions, e.g. at room temperature. Further, it may be accelerated by elevation of the temperature.
The reduction of a carbonyl group can be carried out in an inert solvent such as an ether (e.g. diethyl ether, tetrahydrofuran, dioxane), an alcohol (e.g. methanol, ethanol, isopropanol), benzene, toluene or water at a temperature within a range of from room temperature to the boiling point of the solvent.
Suitable reducing agents which are preferably employed in the reaction are metal hydride complexes such as lithium aluminium hydride, sodium borohydride, bis-(2-methoxyethoxy) aluminium chloride or sodium aluminium diethyl dihydride, palladium on charcoal or platinum oxide.
A spiro amine derivative of the formula (IV) can be prepared by condensation of an oxoindole derivative of the formula:
wherein Rl and R2 are each as defined above with a dihalide of the formula:
wherein Z is as defined above, optionally followed by reduction of an amide group to give a compound of the formula:
wherein Rl, R2 and W are each as defined above, followed, by debenzylation of the latter.
The condensation reaction of the compound (V) with the compound (VI) can be carried out in an inert solvent such as an aromatic hydrocarbon (e.g. benzene, toluene, xylene) at temperature with a range of from room temperature to the boiling point of the solvent inclusive. A suitable condensation agent is a metal hydride (e.g. sodium hydride, calcium hydride), metal alkoxide (e.g. sodium ethoxide, potassium t-butoxide) or sodium amide.
The debenzylation can be carried out by a conventional catalytic hydrogenation procedure, or by treating the compound (VII) with a compound of the formula:
wherein R8 is a C1 - C4 alkyl group or a benzyl group followed by hydrolysis or hydrogenolysis of the compound of the formula:
wherein R', R2, W and R8 are each as defined above.
Specific examples of spiro amine derivatives within the formula (I) are as follows: 1 -(2-hydroxy-3-phenoxypropyl)- 1-methyl-2-oxo-indoline-3-spiro-4' -piperidine
1 '-(2-hydroxy-3-phenoxypropyl)- 1-ethyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(2-hydroxy-3-phenoxypropyl)-1-methylindoline-3-spiro-4'-piperidine
1'-(2-hydroxy-3-phenoxypropyl)-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo (3,2,1 ii )quinoline- t-spiro-4 -piperidine
1 (?-m(1 ,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-methyl-2-oXo-indoline-3-spiro-4' - piperidine
1'- (2- (6-methyl- 1, 4-benzodioxan-2-yl)-2-hydroxy-ethyl)- 1-methyl-2-oxo-indoline-3- spiro-4' -piperidine
1'-(2-(6-methoxy-1 ,4-bensodioxan-2-yl)-2-hydroxyethyl)-1-methyl-2-oxo-indoline-3- spiro-4'-piperidine 1 '-(2-(1 ,4-bensodioxan-2-yl)-2-hydroxyethyl)-2-oxo-1,2,5 ,6-tetrahydro-4Hpyrrolo(3,2, 1-ij) quinoline-1-spiro-4'-piperidine
1 ' -(2-hydroxy-3-( 1-naphthyloxy)propyl)-2-oxo-1,2 2,5 ,6-tetrahydro-4H-pyrrolo (3,2,1- ij)quinoline-1-spiro-4'-piperidine 1 '-(2-hydroxy-3-(1-naphthyloxy)propyl)-1-ethyl-2-oXo-indoline-3-spiro-4'-piperidine 1 '-(2-(1 ,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-propyl-2-oXo-indoline-3-spiro-4'- piperidine 1 '-(2-(1 ,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-ethyl-2-oxo-indoline-3-spiro-4'- piperidine 1' -(2-(1 ,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-methylindoline-3-spiro-4' -piperidine 1 '-(2-hydroxy-3-(2-chlorophenoxy)propyl)- 1-methyl-2-oxo-indoline-3-spiro-4 ' -piperidine 1 '-(2-hydroxy-3-(2-methylphenoxy)propyl)-1-methyl-2-oxo-indoline-3-spiro-4' piperidine 1 '-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-methyl-2-oXo-indoline-3-spiro-4'- piperidine 1 ' -(2-hydroxy-3-(2-cyano-phenoxy)propyl)-1-methyl-2-oXo-indoline-3-spiro-4'- piperidine 1 '-(2-(1 ,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-phenyl-2-oXo-indoline-3-spiro-4'- piperidine 1' -(2-hydroxy-3-( 1-naphthyloxy)propyl)-1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1' -(2-hydroxy-3-(1-naphthyloxy)propyl)- 1-ethyl-indoline-3-spiro-4' -piperidine 1,- (2-phenylethyl)- 1-methylindoline-3-spiro4' -piperidine
1 '-(3-(4-fluorobenzoyl)propyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(3-(4-fluorobenzoyl)propyl)-1-ethyyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(3-(4-fluorobenzoyl)propyl)- 1-propyl-2-oxo-indoline-3-spiro-4'-piperidine 1 -(3-(4-fluorobenzoyl)propyl)-1-phenyl-2-oxo-indoline-3-spiro-4' -piperidine 1 '-(3-(4-fluorobenzoyl)propyl)- 1-methylindoline-3-spiro-4' -piperidine 1' -(3-(4-fluorobenzoyl)propyl)- 1-ethyl-indoline-3-spiro-4' -piperidine 1 '-(4-(4-fluorophenyl)-4-hydroxybutyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(3-(3 ,4-dimethoxybenzoyl)propyl)- 1-methyl-2-oxo-indoline-3-spiro-4' -piperidine 1 '-(3-(4-methoxybenzoyl)propyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(4-(3 ,4, 5-trimethoxyphenyl)-4-hydroxybutyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine 1 '-(2-phenoxyethyl)- 1-ethyl-indoline-3-spiro-4'-piperidine 1' -(2-(4-benzyloxyphenyl)-2-hydroxy- 1 -methylethyl)- 1-methyl-2-oxo-indoline-3-spiro-4' piperidine 1 '-(2-(4-hydroxyphenyl)-2-hydroxy-1-methylethyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine 1' -(2-(4-fluorobenzoyl)ethyl)- 1-methyl-2-oxo-indoline-3-spiro-4' -piperidine 1 '-(3-phenylprop-2-ene- 1-)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1' -(2-benzoylpropyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine 1 '-(3-(4-fluorobenzoyl )propyl)-2-oxo- 1, 2,5 ,6-tetrahydro-4H-pyrrolo(3 ,2,1-ij)quinoline 1-spiro-4 ' -piperidine
1 '-(4- (4-fluorophenyl)-4-hydroxybutyl)-2-oxo- 1 ,2,5,6-tetrahydro-4H-pyrrolo(3,2, 1-ij) quinoline-1-spiro-4'-piperidine 1 '-(3-(4-fluorobenzoyl)propyl)-1 ,2,5 ,6-tetrahydro-4H-pyrrolo(3 ,2, 1-ij )quinoline-1-spiro- 4'-piperidine 1 '-benzoylmethyl)-1 ,2,5 ,6-tetrahydro-4H-pyrrolo-(3,2,1-ij) quinoline-1-spiro-4'piperidine 1' -(2-phenyl-2-hydroxyethyl)-1 ,2,5 ,6-tetrahydro-4H-pyrrolo(3 ,2, 1-ij) quinoline-1-spiro4'-piperidine 1 '-(3-phenoxy-propyl)-1 ,2,5,6-tetrahydro-4H-pyrrolo(3 2, 1-ij) quinoline-1-spiro-4'- piperidine 1 '-(2-phenylethyl-1 ,2,5 ,6-tetrahydro-4H-pyrrolo-(3,2,1-ij)quinoline-1-spiro-4'- piperidine 1 '-(3-(3 ,4-dimethylbenzoyl)propyl)-1-ethyl-indoline-3-spiro-4'-piperidine Spiro amine derivatives within the formula (I) in the free base form can be converted into their pharmaceutically acceptable salts such as acid addition salts or quaternary ammonium salts by treatment with mineral acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid), organic acids (e.g. acetic acid, citric acid, oxalic acid, lactic acid, succinic acid, tartaric acid, cinnamic acid, ascorbic acid), alkyl halides or aralkyl halides.
Spiro amine derivatives within the formula (I) may be brought into a form suitable for administration by known methods.
The present invention additionally provides a pharmaceutical composition comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent or carrier.
For the preparation of such a pharmaceutical composition, a compound within the formula (I) may be mixed with a carrier or diluent such as water, sesame oil, calcium phosphate, starch, talcum, casein, magnesium stearate, methyl cellulose, a polyglycol or tragacanth, sometimes together with a stabilizer and/or emulsifying agent.
The resulting mixture may be processed in a conventional manner to produce, for example, tablets, capsules, pills and ampoules. The usual oral dosage is 1.0 - 500 mg per os daily.
Practical and preferred processes embodying the present invention are illustratively shown in the following Examples.
Example 1 A mixture of 3.0 g of 4-chloro-1-(4-fluoro-phenyl)-1-,1-ethylenedioxybutane, 2.0 g of 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine, 2.8 g of anhydrous potassium carbonate, 0.1 g of potassium iodide and 30 ml of dimethylformamide was refluxed for 2 hours. The resulting mixture was poured into water and was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. To the residual oil were added 60 ml of methanol, 20 ml of water and 10 ml of concentrated hydrochloric acid. The mixture was refluxed for 25 minutes and concentrated in vacuo. The residual oil was made alkaline with 28% aqueous ammonia and extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated. The residual oil was chromatographed over silica gel with ethyl acetate as an elueting agent to give 1'-(3-(4-fluorobenzoyl)propyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine, M.P. 95 - 96.5"C.
Example 2 In the same manner as that described in Example 1, the following compounds were obtained: 1 '-(3-(4-methoxybenzoyl)propyl)- 1 -methyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 75" - 79.50C 1 '-(3-(3,4-dimethoxybenzoyl)propyl)-1-methyl-2-oxo-indoline-3-spiroA'-piperidine M.P. 109"- 112"C 1'-(3-(4-fluorobenzoyl)propyl)-1-ethyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 104 - 107"C 1 '-(3-(4-fluorobenzoyl)propyl)-1-propyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 90"- 91"C 1'-(3-(4-fluorobenzoyl)propyl)-1 -methyl-indoline-3-spiro-4'-piperidine M.P. 980 - 103"C 1'-(3-(4-fluorobenzoyl)propyl)-1-ethyl-indoline-3-spiro-4'-piperidine dihydrochloride M.P. 214 - 216"C 1'-(3-(4-fluorobenzoyl)propyl)-1-phenyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 116.5"- 117"C 1'-(3-(4-fluorobenzoyl)propyl)-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo(3,2,1-ij)quinolinel-spiro-4'-piperidine M.P. 105"- 109"C 1' -(3-(4-fluorobenzoyl)propyl)-1 2,5,6-tetrahydro-4H-pyrrolo(3,2,1-ij)quinoline-1-spiro- 4'-piperidine dihydrochloride M.P. 248 - 249"C Example 3 A mixture of 1.63 g of 2-phenoxyethyl chloride, 1.5 g of 1-methyl-2-oxo-indoline-3-spiro4'-piperidine, 1.44 g of anhydrous potassium carbonate, 0.1 g of potassium iodide and 30 ml of dimethylformamide was stirred at 900 - 100"C for 5 hours. The resulting mixture was poured into water and was extracted with diethylether. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The oil thus obtained was treated with hydrochloric acid to give 1'-(2-phenoxyethyl)-1-methyl-2-oxo-indoline-3-spiro- 4'-piperidine hydrochloride M.P. 206 - 210 C Example 4 In the same manner as that described in Example 3, the following compounds were obtained: 1 '-cinnamyl-1-methyl-2-oxo-indoline-3-spiro-4'-piperidine hydrochloride M.P. 252 - 255"C 1 '-(2-phenylethyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine hydrochloride M.P. 167.5"- 169"C 1 '-(2-phenylethyl)-1-methyl-indoline-3-spiro-4'-piperidine dihydrochloride M.P. > 280"C 1' -(2-phenylethyl)- 1-phenyl-2-oxo-indoline-3-spiro-4' -piperidine hydrochloride M.P. 128 - 137"C 1'-(2-(4-fluorobenzoyl)ethyl)-1-methyl-2-oxo-indoline-3-spiro-4'-piperidine hydrochloride M.P. 196"- 200"C Example 5 A mixture of 0.4 g of 1'-(3-(4-fluorobenzoyl)-propyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine, 1.0 g of sodium borohydride and 20 ml of isopropyl alcohol was refluxed for 30 minutes.
The resulting mixture was poured into water and was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The residual solid was washed with diisopropylether to give 1'-(4-(4-fluorophenyl) 4-hydroxy-butyl)-1-methyl-2-oxo-indoline-3-spiro-4 '-piperidine M.P. 126.5"- 127.5"C Example 6 In the same manner as that described in Example 5, the following compounds were obtained: 1'-(4-(4-fluorophenyl)-4-hydroxybutyl)-2-oxo-1,2,5-6-tetrahydro-4H-pyrrolo(3,2,1- ij)quinoline-1-spiro-4'-piperidine M.P. 137 - 141"C 1 ' -(4-(3,4-dimethoxyphenyl)-4-hydroxybutyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidine M.P. 114"- 122"C 1'-(4-(4-fluorophenyl)-4-hydroxybutyl)-1-ethyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 1310 - 134 C Example 7 A mixture of 3.8 g of p-benzyloxy-a-bromopropiophenone, 2 g of 1-methyl-2-oxo indoline-3-spiro-4'-piperidine, 2 g of sodium bicarbonate and 30 ml of dimethyl-formamide was stirred for 5 hours at room temperature.
The resulting mixture was poured into water and was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The oil thus obtained was washed with n-hexane to give 1'-(1-(4 benzyloxybenzoyl)ethyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine IR vC=0 1680 - 1710 cm~ Example 8 A mixture of 4.5 g of 1'- (1- (4-benzyloxybenzoyl)-ethyl)- 1-methyl-2-oxo-indoline-3-spiro- 4'-piperidine, 5.6 of sodium borohydride and 150 ml of isopropyl alcohol was refluxed for 1 hour. The resulting mixture was poured into water and was extracted with ethyl acetate.
The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude solid was recrystallized from ethanol to give 1'-(2-(4-benzyloxy phenyl)-2-hydroxy. 1-methylethyl)-1-methyl-2-oxo-indoline-3-spiro-4 ' -piperidine.
M.P 1950 - 199"C The mother liquor was concentrated in vacuo and was chromatographed over silica gel to give the isomer.
M.P. 9350 - 98.5"C Example 9 A mixture of 0.7 g of 1'-(2-(4-benzyloxyphenyl)-2-hydroxy-1-methylethyl)-1-methyl-2- oxo-indoline-3-spiro-4'-piperidine (melting point 195 - 199"C), 0.1 g of 10% palladium on charcoal and 120 ml of ethanol was vigorously stirred under atmospheric hydrogen at room temperature, until an equimolar amount of hydrogen was consumed. The catalyst was filtered off, and the filtrate was concentrated in vacuo.
The solid thus obtained was washed with diisopropyl ether to give 1'-(2-(4hydroxyphenyl)-2-hydroxy-1 -methylethyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 223"- 225"C Example 10 A mixture of 1.7 g of 1-phenoxy-2, 3-epoxypropane, 2 g of 1-methyl-2-oxo-indoline-3spiro-4'-piperidine and 120 ml of ethanol was refluxed for 3 hours. The resulting mixture was concentrated and crystallized from diisopropyl-ether to give 1'-(2-hydroxy-3- phenoxypropyl)- 1-methyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 104"- llO"C Example 11 In the same manner as that described in Example 10, the following compounds were obtained: 1 ' 1-naphthyloxy)propyl)-1-methyl-2-oxo-indoline-3-spiro-4'-piperidine M.P. 148.5"- 150.5"C 1' -(2-hydroxy-3-( 1 -naphthyloxy)propyl)-2-oxo-1 ,2,5 ,6-tetrahydro-4H-pyrrolo(3 ,2, 1- ij)quinoline-1-spiro-4'-piperidine M.P. 113 - 119"C 1' -(2-hydroxy-3-(1 -naphthyloxy)-propyl)- 1-ethyl-indoline-3-spiro-4' -piperidine M.P. 114"- 118"C Example 12 A mixture of 2.9 g of 1-(1,4-benzodioxan-2-yl)-2-bromoethanol, 2 g of 1-methyl-2-oxoindoline-3-spiro-4'-piperidine, 1.9 g of sodium carbonate and 30 ml of dimethylformamide was stirred for 1.5 hours at 100 "C. The resulting mixture was poured into water and extracted with ethyl acetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo.
The residual oil was chromatographed over silica gel and washed with diisopropylether to give 1'-(2-(1,4-benzodioxan-2-yl)2-hydroxyethyl)-1-methyl-2-oxo-indoline-3-spiro-4'- piperidme M.P. 113"- 128"C Example 13 In the same manner as that described in Example 12, 1'-(2-(1,4-benzodioxan-2-yl)-2 hydroxyethyl)-2-oxo-1 ,2,5,6-tetrahydro-4H-pyrrolo(3 ,2,1-ij)quinoline-1-spiro-4'- piperidine was obtained.
M.P. 197 - 207"C Reference Example A mixture of 15.1 g of 1'-benzyl-1-methyl-2-oxo-indoline-3-spirn-4'-pipendine, 33.5 g of benzyloxy-carbonyl chloride and 530 ml of toluene was refluxed for 6 hours. The resulting mixture was poured into water and extracted with ethylacetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The oil thus obtained was washed with n-hexane to give 1 '-benzyloxycarbonyl- 1-methyl-2-oxo-indoline3-spiro-4'-piperidine.
A mixture of 12 g of the solid thus obtained, 21.6 g of water, 7.2 g of 5% palladium on charcoal and 500 ml of ethanol was vigorously stirred under atmospheric hydrogen at room temperature, until the reaction was complete. The catalyst was filtered off, and the filtrate was concentrated in vacuo. The solid thus obtained was washed with diisopropylether to give 1-methyl-2-oxo-indoline-3-spiro-4 ' -piperidine.
M.P. 146"- 151"C WHAT WE CLAIM IS: 1. A compound of the formula
wherein R' is a hydrogen atom, a C1 - C4 alkyl group, a phenyl group which is unsubstituted or substituted by a halogen atom, a C1 - C4 alkyl group or a C1 - C4 alkoxy group, R2is absent or R' and R2 together form a C1 - C4 alkylene radical and thus together with the indoline nucleus define a ring, W is an oxygen atom or two hydrogen atoms and R is a group of the formula:
(wherein A is a C, - C4 alkylene, X is absent or is a carbonyl group, an oxygen atom, the radical ,CH-OH or the radical -CH=CH- and R3, R4 and R are each optionally present and are each, independently of one another, a Cl - C4 alkyl group, a C1 - C4 alkoxy group, a benzyloxy group, a halogen atom or a hydroxy group) or (b) R6-CHCH2 OH (wherein R6 is a group of the formula:
(wherein R7 is optionally present and is a halogen atom, a cyano group, a C1 - C4 alkyl group, a Cl - C4 alkoxy group or a hydroxy group),
(wherein R7 is as defined above) or
(wherein R7 is as defined above)), or a pharmaceutically acceptable salt thereof.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (18)

**WARNING** start of CLMS field may overlap end of DESC **. Example 13 In the same manner as that described in Example 12, 1'-(2-(1,4-benzodioxan-2-yl)-2 hydroxyethyl)-2-oxo-1 ,2,5,6-tetrahydro-4H-pyrrolo(3 ,2,1-ij)quinoline-1-spiro-4'- piperidine was obtained. M.P. 197 - 207"C Reference Example A mixture of 15.1 g of 1'-benzyl-1-methyl-2-oxo-indoline-3-spirn-4'-pipendine, 33.5 g of benzyloxy-carbonyl chloride and 530 ml of toluene was refluxed for 6 hours. The resulting mixture was poured into water and extracted with ethylacetate. The extract was washed with water, dried over anhydrous sodium sulfate and concentrated in vacuo. The oil thus obtained was washed with n-hexane to give 1 '-benzyloxycarbonyl- 1-methyl-2-oxo-indoline3-spiro-4'-piperidine. A mixture of 12 g of the solid thus obtained, 21.6 g of water, 7.2 g of 5% palladium on charcoal and 500 ml of ethanol was vigorously stirred under atmospheric hydrogen at room temperature, until the reaction was complete. The catalyst was filtered off, and the filtrate was concentrated in vacuo. The solid thus obtained was washed with diisopropylether to give 1-methyl-2-oxo-indoline-3-spiro-4 ' -piperidine. M.P. 146"- 151"C WHAT WE CLAIM IS:
1. A compound of the formula
wherein R' is a hydrogen atom, a C1 - C4 alkyl group, a phenyl group which is unsubstituted or substituted by a halogen atom, a C1 - C4 alkyl group or a C1 - C4 alkoxy group, R2is absent or R' and R2 together form a C1 - C4 alkylene radical and thus together with the indoline nucleus define a ring, W is an oxygen atom or two hydrogen atoms and R is a group of the formula:
(wherein A is a C, - C4 alkylene, X is absent or is a carbonyl group, an oxygen atom, the radical ,CH-OH or the radical -CH=CH- and R3, R4 and R are each optionally present and are each, independently of one another, a Cl - C4 alkyl group, a C1 - C4 alkoxy group, a benzyloxy group, a halogen atom or a hydroxy group) or (b) R6-CHCH2 OH (wherein R6 is a group of the formula:
(wherein R7 is optionally present and is a halogen atom, a cyano group, a C1 - C4 alkyl group, a Cl - C4 alkoxy group or a hydroxy group),
(wherein R7 is as defined above) or
(wherein R7 is as defined above)), or a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1, wherein W is an oxygen atom.
3. A compound according to Claim 1, wherein R is a group of the formula:
(wherein R3, R4, R5, A and R7 are each as defined in Claim 1).
4. The compound according to Claim 1, wherein W is an oxygen atom and R is a group of the formula:
(wherein R3, R4 and R5 are each as defined in Claim 1).
5. A compound according to Claim 1, wherein W is an oxygen atom and R is a group of the formula:
(wherein R7 is as defined in Claim 1).
6. 1'-(3-(4-fluorobenzoyl)propyl)-1-methyl-2-oxo-indoline-3-spiro-4'-piperidine.
7. 1 '-(3-(4-fluorobenzoyl)propyl)- 1-propyl-2-oxo-indoline-3-spiro-4' -piperidine.
8. 1 -(2-hydroxy-3-phenoxypropyl)- 1-methyl-2-oxo-indoline-3-spiro-4' -piperidine .
9. 1'-(3-(4-fluorobenzoyl)propyl)-2-oxo-1,2,5,6-tetrahydro-4H-pyrrolo(3,2,1- ij)quinoline- 1-spiro-4'-piperidine.
10. 1 ' -(2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl)-1-methyl-2-oXo-indoline-3-spiro-4'- piperidine.
11. 1'-(2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl)-2-oxo-1,2,5,6-tetrahydro-4H- pyrrolo(3,2,1-ij )quinoline- 1-spiro-4' -piperidine.
12. A process for producing a spiro amine derivative of the formula:
wherein R, Rl, R2, and W are each as defined in Claim 1, or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of the formula:
wherein R3, R4, R5 and A are each as defined in Claim 1, Z is a halogen atom and Y is absent or is a carbonyl group, a protected carbonyl group, an oxygen atom, the radical =CH-OH or the radical -CH=CH-, or a compound of the formula: R6 B wherein R6 is as defined in Claim 1 and B is a group of the formula:
(wherein Z is as defined above) with a spiro amine derivative of the formula:
wherein Rl, R2 and W are each as defined in Claim 1, optionally followed by reduction of a carbonyl group, or by hydrolysis of a protected carbonyl group, and optionally salifying the resultant product.
13. A process according to Claim 12, wherein W is an oxygen atom.
14. A process according to Claim 12, wherein R is a group of the formula:
wherein R3, R4, R5 and R7 are each as defined in Claim 1.
15. A pharmaceutical composition comprising at least one compound of the formula (I), given and defined in Claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent or carrier.
16. The compounds of the formula (I), given and defined in Claim 1 other than those claimed in Claims 6 to 11 which are specifically disclosed herein.
17. Processes according to Claim 12, for producing a spiro amine of the formula (I), given and defined in Claim 1, which processes are substantially as herein described and exemplified.
18. Spiro amines of the formula (I), given and defined in Claim 1, whenever produced by a process according to any of Claims 12 to 14 and 17.
GB1995978A 1978-05-16 1978-05-16 Spiro amines their production and compositions containing them Expired GB1575800A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1995978A GB1575800A (en) 1978-05-16 1978-05-16 Spiro amines their production and compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1995978A GB1575800A (en) 1978-05-16 1978-05-16 Spiro amines their production and compositions containing them

Publications (1)

Publication Number Publication Date
GB1575800A true GB1575800A (en) 1980-10-01

Family

ID=10137988

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1995978A Expired GB1575800A (en) 1978-05-16 1978-05-16 Spiro amines their production and compositions containing them

Country Status (1)

Country Link
GB (1) GB1575800A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028638A1 (en) * 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
EP1880996A1 (en) 2002-06-14 2008-01-23 Syngenta Limited Spiroindolinepiperidine derivatives
US20090042921A1 (en) * 2003-12-12 2009-02-12 Syngenta Participations Ag Spiroindoline derivatives having insecticidal properties
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786107B2 (en) 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US7973162B2 (en) 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880996A1 (en) 2002-06-14 2008-01-23 Syngenta Limited Spiroindolinepiperidine derivatives
US8309567B2 (en) * 2003-12-12 2012-11-13 Syngenta Crop Protection Llc Spiroindoline derivatives having insecticidal properties
US20090042921A1 (en) * 2003-12-12 2009-02-12 Syngenta Participations Ag Spiroindoline derivatives having insecticidal properties
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
US8497295B2 (en) 2004-08-19 2013-07-30 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
US8367691B2 (en) 2004-08-19 2013-02-05 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8258148B2 (en) 2004-08-19 2012-09-04 Vertex Pharmaceutical Incorporated Spiroindoline modulators of muscarinic receptors
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8546417B2 (en) 2005-09-09 2013-10-01 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
WO2007028638A1 (en) * 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
US8883816B2 (en) 2005-09-09 2014-11-11 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
US8193208B2 (en) 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
US8304423B2 (en) 2006-02-22 2012-11-06 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
US8003660B2 (en) 2006-02-22 2011-08-23 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786107B2 (en) 2006-08-18 2010-08-31 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7973162B2 (en) 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors

Similar Documents

Publication Publication Date Title
US4233307A (en) Spiro-4'-piperidine compounds and their pharmaceutical compositions
US4353900A (en) 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4113869A (en) Tetrahydroisoquinoline basic ethers and pharmaceutical compositions and methods employing them
US4806650A (en) Process for preparing 1-deoxynojirimycin and N-derivatives thereof
US4259338A (en) Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof
US4353901A (en) 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
GB1575800A (en) Spiro amines their production and compositions containing them
US4360519A (en) Analgesic method using a morpholine compound
SK283877B6 (en) Process for producing derivatives of 4a,5,9,10,11,12,-hexahydro- 6H-benzofuro[3a,3,2-ef][2]benzazepine
SU688127A3 (en) Method of obtaining phenylethylamines or their salts
NO170919B (en) SHAPE FOR BAND METAL COIL AND PROCEDURE FOR AA SHAPE IT
GB1579878A (en) Aralkenyl-aminomethyl-naphtalene derivatives
US5852019A (en) Pyrimidinylpyrazole derivatives
US4478750A (en) 1-Phenyl-azepinoindoles
US4075346A (en) CNS depressant γ-(secondary amino)-ortho-nitro-butyrophenones
US3328396A (en) 3, 8-di-substituted-3, 8-diazabicyclo [3.2.1] octanes
US4251659A (en) Polyfluorohydroxyisopropyl-heterocyclic compounds
US3317527A (en) 3a and 5a tertiaryamino cycloalkylene of 5 to 7[alpha]benzofuranols
US4010280A (en) Phenoxyalkylamine derivatives and preparation thereof
US3822266A (en) (3-(1-piperazinyl)-2-hydroxy-propoxy)acetanilides
US4754037A (en) Process for preparing N-methyl derivatives of ergoline
EP0301549A1 (en) 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them
US4409218A (en) Analgesic method
US5077295A (en) Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
US4387230A (en) Process for preparing a dihydropyridine derivative

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee